The molecular pharmacology of doxorubicin in vivo.
Cummings
J
J
Imperial Cancer Research Fund, Western General Hospital, Edinburgh, U.K.
Anderson
L
L
Willmott
N
N
Smyth
J F
JF
D001665:Binding Sites; D002462:Cell Membrane / Q000378:metabolism; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004273:DNA, Neoplasm / Q000378:metabolism; D004317:Doxorubicin / Q000494:pharmacology* / Q000627:therapeutic use; D004798:Enzymes / Q000378:metabolism; D005609:Free Radicals; D006801:Humans; D009369:Neoplasms / Q000201:enzymology
D004273:DNA, Neoplasm; D004798:Enzymes; D005609:Free Radicals; D004317:Doxorubicin; D004250:DNA Topoisomerases, Type II